Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
16.23
+0.14 (+0.87%)
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
34
35
Next >
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
March 24, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst...
Via
StockStory
Topics
Artificial Intelligence
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
↗
March 23, 2025
Via
The Motley Fool
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
March 21, 2025
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its...
Via
StockStory
Topics
Artificial Intelligence
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up
↗
March 21, 2025
Jefferies acknowledged acute liver failure could signal a new safety risk but maintained that the high unmet need for DMD treatments supports the bull case.
Via
Stocktwits
8 Analysts Have This To Say About Sarepta Therapeutics
↗
February 27, 2025
Via
Benzinga
Earnings Scheduled For February 26, 2025
↗
February 26, 2025
Via
Benzinga
2 Growth Stocks to Buy Hand Over Fist in February
↗
February 09, 2025
Via
The Motley Fool
Nvidia, Meta, Sarepta, D-Wave, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
↗
March 18, 2025
U.S. stock markets traded lower on Tuesday as investors awaited the Federal Reserve's interest rate decision. The Dow Jones Industrial Average slipped 0.6% to 41,581.31
Via
Benzinga
Topics
Economy
Stocks
12 Analysts Have This To Say About Sarepta Therapeutics
↗
March 18, 2025
Via
Benzinga
Wall Street Falters, Magnificent Seven Hit 7-Month Lows, Gold Rockets On Haven Demand: What's Driving Markets Tuesday?
↗
March 18, 2025
Volatility returned to Wall Street on Tuesday, with all major indexes trading in negative territory by midday in New York.
Via
Benzinga
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge
↗
March 18, 2025
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
March 18, 2025
Via
Benzinga
Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today
March 18, 2025
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported the death of a Duchenne muscular dystrophy patient following treatment with...
Via
StockStory
Discover the top movers in Tuesday's pre-market session.
↗
March 18, 2025
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
Via
Chartmill
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
↗
March 18, 2025
Sarepta shares fell after reporting a patient death linked to Elevidys. The case involved acute liver failure, with a CMV infection as a potential factor.
Via
Benzinga
Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies
↗
March 18, 2025
The patient also had a recent CMV infection, which the company said could have contributed.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
March 18, 2025
Via
Benzinga
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
↗
March 10, 2025
Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting.
Via
Benzinga
SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) showing high EPS and FCF growth while beating expectations
↗
March 04, 2025
A fundamental analysis of (NASDAQ:SRPT): SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) may be suited for growth investing, we'll explore why in this article.
Via
Chartmill
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
March 04, 2025
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
February 28, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript
↗
February 26, 2025
SRPT earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On Revenue
February 26, 2025
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% year on year to $658.4 million. Its non-GAAP profit of $1.90 per share was...
Via
StockStory
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
February 26, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
↗
February 26, 2025
Via
Benzinga
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
February 25, 2025
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know.
Via
StockStory
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
February 19, 2025
Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?
Via
MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
↗
February 14, 2025
Via
Benzinga
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
February 14, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
February 12, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
